ClinicalTrials.gg
CompletedNCT01930331Updated Mar 14, 2018

Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO

A Phase 4 interventional study of artemisinin/naphthoquine and dihydroartemisinin/piperaquine phosphate in Plasmodium Falciparum and Malaria, Falciparum, sponsored by Ifakara Health Institute. Completed at 1 site in Tanzania. Open to participants aged 6 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-03-14.

Sponsored by Ifakara Health Institute · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
6 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Malaria, Falciparum with a site in Tanzania — none open to participants now, none under way, none of them phase 3. Malaria, Falciparum · Tanzania.

Enrollment
32nd of 41
60 · median 300
Started
2014
with 5 others
Phase 4
9 of 43
none open now
Registered
19th of 43
by date
Lead sponsor
2 of 43
Ifakara Health Institute

Among the 43 studies in Malaria, Falciparum with a site in Tanzania, this one is the 32nd largest by enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2014, is one of 9 in phase 4, and was the 19th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

None of the 43 studies in Malaria, Falciparum with a site in Tanzania is open now. The open studies under Malaria, Falciparum, anywhere →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies in Malaria, Falciparum with a site in Tanzania as a file.
02

Study summary

Phase IV, single center, 2 arms randomized controlled, open label study. Study will be conducted over a period of 42 days to determine the safety, tolerability, pharmacokinetics and efficacy of ARCO.

Read the detailed description

Evaluation of safety and tolerability of the administration of ARCO and Eurartesim in terms of blood biochemistry, full blood count, ECG assessments, vital signs and adverse events profile in patients with uncomplicated P. falciparum malaria. Dihydroartemisinin/piperaquine will be used as comparator.

03

Conditions studied

  • Plasmodium Falciparum
  • Malaria, Falciparum

Browse trials for

Keywords

  • Uncomplicated Plasmodium falciparum Malaria
04

Who can participate

Ages eligible
6 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written , in accordance with local practice, provided by patient, for children it will provided by either parents or legal representative and in addition children will provide assent.
  2. Male or female patients between the age of 6 and 60 years (both inclusive)
  3. Body weight between 20 kg and 90 kg (both inclusive)
  4. Presence of mono-infection with P. falciparum (1,000 to 100,000 asexual count/µl of blood) microscopically confirmed.
  5. Fever, as defined by axillary temperature ≥ 37.5°C to ≤ 39.5°C
  6. Ability to swallow oral medication
  7. Ability and willingness to adhere to all study procedures and access health facilities.
  8. Agree to undergo study related procedures including being hospitalized for minimum of 3 days (0,1 and 2), and a follow up of up to 42 days.

Exclusion criteria

Exclusion Criteria:

  1. Patients with signs and symptoms of severe/complicated malaria as described in the WHO guideline(Third Edition 2012) for management of severe malaria(6)(Appendix 1)
  2. Mixed Plasmodial infection.
  3. Severe vomiting, defined as more than three times in the 24 hours prior to inclusion in the study or inability to tolerate oral treatment.
  4. Severe diarrhoea defined as 3 or more watery stools per day.
  5. Presence of other serious or chronic clinical condition requiring hospitalization.
  6. Known history or evidence of disorders such as cardiovascular (including arrhythmia, or QTcB interval greater than or equal to 450 msec), respiratory (including active tuberculosis), history of jaundice, hepatic, renal, gastrointestinal, immunological, neurological (including auditory), endocrine, infectious, , psychiatric, history of convulsions or other abnormality (including head trauma).
  7. Family history of sudden death or of congenital prolongation of the QT interval or any other clinical condition known to prolong the QT interval.
  8. Known congenital prolongation of the QT-interval or any clinical condition known to prolong the QT interval.
  9. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.
  10. Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle .
  11. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.
  12. Any treatment which can induce a lengthening of QT interval, such as:

    i. Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol) ii. Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine) iii. Antidepressive agents, certain antimicrobial agents, including agents of the following classes macrolides (e.g. erythromycin, clarithromycin), fluoroquinolones (e.g. moxifloxacin, sparfloxacin), imidazole and triazole antifungal agents, and also pentamidine and saquinavir iv. Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine), cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide

  13. Known history of , allergic or adverse reactions to artemisinin containing compounds, piperaquine or naphthoquine or to any of the contained in ARCO and Eurartesim.
  14. Antimalarial treatment with different antimalarial drugs as follows i. Piperaquine-based compound, mefloquine, naphthoquine or sulphadoxine/pyrimethamine (SP) within the previous 3 months, ii. Amodiaquine or chloroquine within the previous 6 weeks, and with quinine, halofantrine, lumefantrine-based compounds and iii. Any other antimalarial treatment, antibiotics with antimalarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin) or any herbal products, within the past 14 days
  15. Have received an drug within the past 6 weeks.
  16. Liver function tests:

    i. If Total is normal, exclude the patient if liver function tests ASAT/ALAT ≥ 3xULN ii. If Total Bilirubin is > 1 and ≤ 1.5xULN, exclude the patient if ASAT/ALAT ≥2xULN.

    iii. Total Bilirubin >1.5xULN

  17. level below 9 g/dL.
  18. Serum creatinine levels more than 2 times the in absence of dehydration. In case of important dehydration the creatinine should be lower than 2X ULN after oral/parenteral rehydration.
  19. Female patients must be neither pregnant (as demonstrated by a negative serum pregnancy test) nor lactating, and must be willing to take measures not to become pregnant during the study period and safety follow-up period.
  20. Previous participation in any malaria vaccine trial or received malaria vaccine in any other circumstance
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ARCO treatment

    Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision.

    Drug: artemisinin/naphthoquine

  • Active comparator
    Eurartesim treatment

    Patients in this treatment arm will receive a dose of dihydroartemisinin/piperaquine phosphate (in a fixed oral dose of Eurartesim tablets) over three days (0,1,2). Treatment will be given under supervision.

    Drug: dihydroartemisinin/piperaquine phosphate

Interventions

  • Drugartemisinin/naphthoquine

    Drug page: ArtemisininStudies of ArtemisininArtemisinin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet). The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet)).

    Also known as: ARCO®

  • Drugdihydroartemisinin/piperaquine phosphate

    Drug pages: ArtenimolStudies of ArtenimolArtenimol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PiperaquineStudies of PiperaquinePiperaquine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.

    Also known as: Eurartesim®

06

What researchers measure

Primary outcomes

  1. Number of reported non serious and serious adverse events

    Time frame: Up to 6 Weeks

Secondary outcomes

  1. 12-lead ECG recordings: Heart rate, PR interval, QRS duration, QT interval, QTc (Fridericia and Bazett corrections), any T wave or U-wave morphology.

    For ARCO treatment arm (which will only receive a single dose of ARCO treatment), Holter recording will start 15 minutes before the dose of ARCO, and it will run continuously during 12 hours post dosing. For Eurartesim treatment arm (which will receive three daily doses of Euratertesim treatment), Holter recording will run for 15 minutes before the first dose, and then it will start again 15 minutes before the third dose (last dose) running continuously for 12 hours post dosing.

    Time frame: Holter recording will run continuously during 12 hours after the last dose of treatment

Other outcomes

  1. Frequency of abnormal safety laboratory parameters (hematology, clinical chemistry, urinalysis and coagulation) and clinical parameters (blood pressure, pulse rate, temperature)

    Time frame: weekly up to 6 weeks

07

Study locations

1 site
  • Ifakara Health Institute
    Bagamoyo, 74, Tanzania
08

References and documents

Publications

  • Ali AM, Gausi K, Jongo SA, Kassim KR, Mkindi C, Simon B, Mtoro AT, Juma OA, Lweno ON, Gwandu CH, Bakari BM, Mbaga TA, Milando FA, Hamad A, Shekalaghe SA, Abdulla S, Denti P, Penny MA. Population Pharmacokinetics of Antimalarial Naphthoquine in Combination with Artemisinin in Tanzanian Children and Adults: Dose Optimization. Antimicrob Agents Chemother. 2022 May 17;66(5):e0169621. doi: 10.1128/aac.01696-21. Epub 2022 Apr 25. PubMed 35465706 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Jul 2014, 6 months.

Of 23 phase 4 interventional studies under Malaria, Falciparum, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2013
First posted
Aug 28, 2013
StartActual
Jan 7, 2014
Primary completionActual
Jul 27, 2014
CompletionActual
Jun 1, 2015
Last update
Mar 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01930331
Lead sponsor
Ifakara Health Institute
Responsible party
Sponsor
First posted
Aug 28, 2013
Start date
Jan 7, 2014
Primary completion
Jul 27, 2014
Completion
Jun 1, 2015
Last update
Mar 14, 2018

Study contacts

Salim Abdulla, MD, PhD
principal investigator · Ifakara Health Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Artemisinin

Start the discussion